The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

NRG Oncology launches FORTE, a colorectal cancer prevention clinical trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

NRG Oncology activated FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps, or NRG-CC005), a large, randomized trial of surveillance colonoscopy for participants with a first-time diagnosis of 1 or 2 adenomas.

Participants in the study will be assigned to having their next colonoscopy exam at 5 years and at 10 years or their next colonoscopy exam at 10 years. The study is expected to enroll 9,500 participants (about 4,750 people in each study group). 

The primary objective of the study is to determine when people who had 1 or 2 small benign polyps removed during colonoscopy should have their repeat colonoscopy exam.

Participants in FORTE are also being asked to submit blood, stool, and tissues from polyps to support research into how colorectal cancer develops from a polyp. 

FORTE is being conducted through NCORP, in conjunction with members of the NCTN. The trial will be led by NRG Oncology with the participation of other network organizations: Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and SWOG.

Table of Contents

YOU MAY BE INTERESTED IN

White House

Tracking Trump’s early impact on cancer policy
Research and care disrupted, NCI programs face unpredictable future

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
By Paul Goldberg
Capitol Hill

With a spotlight on vaccines, abortion, Medicaid and Medicare, RFK Jr. goes before the Senate
The MAHA nominee trumpets radical transparency, but offers little clarity on his new agenda

In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
By Claire Marie Porter
Guest Editorial

Cancer research fuels life-saving work

Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 
By Ze’ev Ronai
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account